ImmuneRegen BioSciences, Inc., and BioCure, Inc., will partner to design and develop a novel wound-healing product which will combine wound-healing activity with an easily applied liquid bandage. The combination product will be composed of the potential wound-healing therapeutic ImmuneRegen’s Homspera and BioCure’s GelSpray™, a spray-on liquid bandage that has obtained 510(k) market clearance from the FDA.
“Homspera can directly enhance fibroblast growth,” said Hal Siegel, Ph.D., ImmuneRegen’s vice president and chief scientific officer. “In addition, we have shown Homspera can stimulate blood-forming stem cells to produce white blood cell precursors, particularly, granulocytes and macrophages, which play a role in wound repair. This combination of enhanced fibroblast growth and increased immune system cells suggest a role for Homspera in improving wound and lesion healing.”
BioCure's product was first developed for the U.S. military, but has since been approved for public consumption. It is applied with a dual-syringe which releases an epoxy-like polymer that reacts immediately upon application. Once administered, the dressing flows to the physical geometry of the body, adhering to skin while resisting abrasion and binding to wounded tissue. Once applied, the dressing can be peeled from the wound. It has been targeted to treat traumatic wounds, burns, diabetic ulcers, ostomies, and post-operation wounds. Eventually, the company expects the technology to treat infection and pain while controlling severe bleeding.
"We welcome the opportunity to collaborate with ImmuneRegen on innovative products with the aim of benefiting patients and healthcare practitioners. We believe that the combination of the technologies and experienced R&D teams of both companies could lead to breakthrough treatments in wound healing," said Andrew Maslaveckas, BioCure’s co-founder and chief operating officer.
According to Michael Wilhelm (pictured), ImmuneRegen president and CEO, “This could drive significant partnering opportunities, as we believe wound-healing products remain in high demand. The potential combination could make an excellent product for our soldiers in the battlefield in addition to benefiting the public at large.”
Illustration: ImmuneRegen Biosciences.
ImmuneRegen Biosciences News Release (04/24/08)
AZ Tech News (04/26/08)
East Valley Living (04/28/08)